PsyRx CNS Bio-Tech (XTAE:PSRX) Buyback Yield %: 0.00 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:PSRX PsyRx CNS Bio-Tech Ltd XTAE:PSRX
12 GF Score
Price ₪0.77
! 1 Warning Sign
View Full Analysis

What is PsyRx CNS Bio-Tech Buyback Yield %?

PsyRx CNS Bio-Tech XTAE:PSRX +0.92% 12 Buyback Yield % is 0.00 as of Aug. 23, 2026. GuruFocus rates XTAE:PSRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 243 Drug Manufacturers companies, PsyRx CNS Bio-Tech ranks worse than 411522.22% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

PsyRx CNS Bio-Tech's current buyback yield was 0.00%.

PsyRx CNS Bio-Tech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for PsyRx CNS Bio-Tech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyRx CNS Bio-Tech Buyback Yield % Chart

PsyRx CNS Bio-Tech Annual Data
Trend
Buyback Yield %

PsyRx CNS Bio-Tech Semi-Annual Data
Buyback Yield %

XTAE:PSRX vs ZTS, UTHR, VTRS: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PsyRx CNS Bio-Tech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyRx CNS Bio-Tech Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PsyRx CNS Bio-Tech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where PsyRx CNS Bio-Tech's Buyback Yield % falls into.


XTAE:PSRX
12GF Score
PsyRx CNS Bio-Tech Ltd XTAE:PSRX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PsyRx CNS Bio-Tech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

PsyRx CNS Bio-Tech's Buyback Yield for the fiscal year that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- ( + ) /
=N/A%

PsyRx CNS Bio-Tech's annualized Buyback Yield for the quarter that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- ( + ) /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
PsyRx CNS Bio-Tech (XTAE:PSRX) has a Buyback Yield % of 0.00 as of Aug. 23, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PsyRx CNS Bio-Tech and its competitors. According to the industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 243 companies in the Drug Manufacturers industry.
Is PsyRx CNS Bio-Tech's Buyback Yield % too high?
PsyRx CNS Bio-Tech's current Buyback Yield % is 0.00. Based on the distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 243 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PsyRx CNS Bio-Tech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does PsyRx CNS Bio-Tech's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 243 companies for Buyback Yield %. This places PsyRx CNS Bio-Tech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on PsyRx CNS Bio-Tech and its competitors. PsyRx CNS Bio-Tech's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyRx CNS Bio-Tech stock overvalued right now?
PsyRx CNS Bio-Tech (XTAE:PSRX) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. PsyRx CNS Bio-Tech's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For PsyRx CNS Bio-Tech (XTAE:PSRX), the current Buyback Yield % is 0.00 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyRx CNS Bio-Tech Business Description

Address Arik Einstein 3, Herzliya, ISR, 4610301
PsyRx CNS Bio-Tech Ltd Formerly Cannabotech Ltd is engaged in the research and development of cannabis-based drugs. It is a biomedical company focused on the benefits of cannabinoids and medicinal mushrooms, applying the pure power of nature and science to health issues.
12GF Score

Get the complete analysis for XTAE:PSRX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.77
Price